KalVista Pharmaceuticals Announced The UK Medicines And Healthcare Products Regulatory Agency Has Awarded The Promising Innovative Medicine Designation For Sebetralstat For On-demand Treatment Of Hereditary Angioedema
KalVista Pharmaceuticals Announced The UK Medicines And Healthcare Products Regulatory Agency Has Awarded The Promising Innovative Medicine Designation For Sebetralstat For On-demand Treatment Of Hereditary Angioedema
KalVista 製藥公司宣佈，英國藥品和保健產品監管局已授予用於按需治療遺傳性血管性水腫的 Sebetralstat 具有前景的創新藥物稱號
KalVista Pharmaceuticals Announced The UK Medicines And Healthcare Products Regulatory Agency Has Awarded The Promising Innovative Medicine Designation For Sebetralstat For On-demand Treatment Of Hereditary Angioedema
KalVista 製藥公司宣佈，英國藥品和保健產品監管局已授予用於按需治療遺傳性血管性水腫的 Sebetralstat 具有前景的創新藥物稱號
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。